Genentech/Biogen Idec Submit Rituxan sBLA For Front-Line Non-Hodgkin’s Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Expanded indication could be approved by February 2006, contingent upon a requested priority review.
You may also be interested in...
Rituxan Approved For First-Line Non-Hodgkin's Lymphoma
A second sBLA is pending for the treatment of refractory rheumatoid arthritis.
Rituxan Approved For First-Line Non-Hodgkin's Lymphoma
A second sBLA is pending for the treatment of refractory rheumatoid arthritis.
Genentech/Biogen Idec Submit Rituxan sBLA For Rheumatoid Arthritis
Filing is second in two weeks for the biologic, following recent sBLA submission for front-line non-Hodgkin's lymphoma treatment.